Physician profile
David E Powell
NPI 1013902477
$162,180.83
in general payments reported to CMS, 2019-2025
32 companies · $20K in 2025
The $20K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $4,435 · 2021: $249 · 2022: $63K · 2023: $47K · 2024: $15K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Travel and Lodging: $3,337 · Food and Beverage: $2,606 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,943.31 |
| Travel and Lodging | $3,336.84 |
| Food and Beverage | $2,606.23 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $144,112.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,729.30 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $3,976.75 | 2019-2025 | Eliquis, Camzyos |
| Lilly USA, LLC | $3,100.00 | 2019 | |
| Amgen INC. | $464.66 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $438.54 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $364.85 | 2020-2022 | |
| Abbott Laboratories | $284.04 | 2019-2025 | Cardiomems |
| Pfizer INC. | $279.47 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $200.35 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $185.24 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $156.43 | 2023 | |
| Baxter Healthcare | $130.77 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.70 | 2019-2025 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $88.18 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $81.90 | 2020-2023 | |
| Astellas Pharma US INC | $79.99 | 2020 | |
| Heartflow, INC. | $60.91 | 2023-2024 | Ffrct |
| Merck Sharp & Dohme LLC | $55.31 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $44.61 | 2022-2023 | Onpattro |
| Boston Scientific Corporation | $38.69 | 2019-2024 | Watchman Flx |
| Azurity Pharmaceuticals, INC. | $32.22 | 2024-2025 | Edarbi, Edarbyclor |
| Esperion Therapeutics, INC. | $28.00 | 2021-2025 | Nexletol |
| Irhythm Technologies, INC. | $27.63 | 2019 | |
| Bracco Diagnostics INC. | $19.46 | 2022 | |
| Cvrx, INC. | $18.45 | 2024 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $17.07 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $16.25 | 2024 | Arcalyst |
| Amryt Pharma Holdings Ltd | $15.66 | 2020 | |
| Gilead Sciences, INC. | $15.00 | 2019 | |
| Akcea Therapeutics, INC. | $13.78 | 2021 | |
| Althera Pharmaceuticals LLC | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.